Big Board Alerts

Hikma and CanariaBio sign exclusive licensing agreement to bring Oregovomab to the Middle East and North Africa

Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces an exclusive license agreement with CanariaBio, a Korean biopharmaceutical company focused on the development and commercialization of immunotherapies for cancer. Under the terms of the agreement, Hikma has an exclusive license to commercialise Oregovomab in 18 Middle East and North Africa (MENA) countries.

Oregovomab is a murine monoclonal antibody and a first-in-class anti-CA125 immunotherapy drug candidate. It is being tested in combination with carboplatin and paclitaxel for patients with advanced ovarian cancer. Oregovomab has obtained Orphan Drug Designations from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

“Ovarian cancer is ranked as the eighth most common cancer in women globally[1] and the first-line treatment for this disease has not changed for many years. We have been actively expanding our oncology portfolio through R&D and in-licensing, in order to address unmet medical needs in different types of cancer and bring renewed hope to cancer patients in the MENA region,” said Mazen Darwazah, Hikma’s Executive Vice Chairman and President of MENA. “We believe Oregovomab can potentially improve the treatment outcomes for patients with advanced primary ovarian cancer. We are excited about the collaboration with CanariaBio as it will bring hope to our cancer patients in MENA and strengthen our oncology portfolio.”

The post Hikma and CanariaBio sign exclusive licensing agreement to bring Oregovomab to the Middle East and North Africa appeared first on Pharma Journalist.

 

Latest Articles

DON’T MISS THE OPPORTUNITY TO JOIN OUR MARKET SUMMARY REPORT FOR A LIMITED TIME

By submitting this form on our website, you agree that we may collect and use your personal information for marketing, and for other purposes as set forth in our privacy policy, which we encourage you to review.